Sugi Predict

Sugi Predict / Targets / BRS3

BRS3

Bombesin receptor subtype-3 · P32247 · BRS3 on Sugi Atlas →

17,030 patent compounds predicted against BRS3, 8,039 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1085078 SCHEMBL1085078 1.00 20/20
SCHEMBL1085132 SCHEMBL1085132 1.00 20/20
SCHEMBL1085358 SCHEMBL1085358 1.00 20/20
SCHEMBL1085548 SCHEMBL1085548 1.00 20/20
SCHEMBL1085577 SCHEMBL1085577 1.00 20/20
SCHEMBL1085743 SCHEMBL1085743 1.00 20/20
SCHEMBL1085809 SCHEMBL1085809 1.00 20/20
SCHEMBL1085813 SCHEMBL1085813 1.00 20/20
SCHEMBL1085894 SCHEMBL1085894 1.00 20/20
SCHEMBL1085910 SCHEMBL1085910 1.00 20/20
SCHEMBL1085925 SCHEMBL1085925 1.00 20/20
SCHEMBL1085952 SCHEMBL1085952 1.00 20/20
SCHEMBL1090353 SCHEMBL1090353 1.00 20/20
SCHEMBL1090354 SCHEMBL1090354 1.00 20/20
SCHEMBL1090451 SCHEMBL1090451 1.00 20/20
SCHEMBL1090452 SCHEMBL1090452 1.00 20/20
SCHEMBL1090453 SCHEMBL1090453 1.00 20/20
SCHEMBL1090479 SCHEMBL1090479 1.00 20/20
SCHEMBL1090487 SCHEMBL1090487 1.00 20/20
SCHEMBL1090782 SCHEMBL1090782 1.00 20/20

Clinical trials — most relevant to BRS3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause PHASE4COMPLETED
Medication, Weight Gain and GI Hormones PHASE4COMPLETED
Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease PHASE4COMPLETED
Ondansetron in the Prevention of Hypotension in Patients Undergoing Spinal Anesthesia PHASE4UNKNOWN
PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial) PHASE3RECRUITING
Comp Granisetron Midazolam Comb in Lap Children PHASE3UNKNOWN
Psychopharmacology for Cocaine Dependence - Buspirone PHASE2COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia PHASE2COMPLETED
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management PHASE2RECRUITING
Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance PHASE1/PHASE2WITHDRAWN
A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids. PHASE2COMPLETED
Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough PHASE2NOT_YET_RECRUITING
Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36 PHASE1/PHASE2COMPLETED
A Prevention Trial in Subjects at High Risk for Breast Cancer PHASE2COMPLETED
68Ga-NOTA-RM26 PET/CT in Prostate Cancer Patients PHASE1UNKNOWN
68Ga-NOTA-PEG2-RM26 PET/CT, First in Man Study PHASE1UNKNOWN
68Ga-NOTA-Aca-BBN(7-14) PET/CT in Patients With Primary Gliomas EARLY_PHASE1UNKNOWN
Relationship of Brain Natriuretic Peptide (BNP) Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome nanCOMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment nanNOT_YET_RECRUITING
Preemptive Oral Gabapentin and Tramadol on Postoperative Pain After Knee Arthroscopy nanCOMPLETED
Impact of Barostimulation on Hemodynamics in Adults With Heart Failure nanNOT_YET_RECRUITING
Auricular Vagus Stimulation in Obesity nanACTIVE_NOT_RECRUITING
The Effect of Calcium on Postprandial Lipid Profile and Appetite nanCOMPLETED
The Lean Living Study nanCOMPLETED
Effect of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Plasma Insulin Levels nanRECRUITING
Gastrointestinal Hormonal Regulation of Obesity nanCOMPLETED
Selective Activation of the Adrenomedullin Receptors in Migraine nanNOT_YET_RECRUITING
Acylated Ghrelin Response to Acute Exercise in Obesity nanCOMPLETED
Metabotropic Receptors For Glutamate Type 3 In Parkinson's nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a BRS3 binder may also engage these)

ProteinNameSimilarity
O54798 — 1.000 O54798 →
Q6H2Y3 — 1.000 Q6H2Y3 →
Q8K418 — 1.000 Q8K418 →
O97967 — 1.000 O97967 →
P35371 — 1.000 P35371 →
TRHR Thyrotropin-releasing hormone receptor 0.986 landscape →
Q01717 — 0.983 Q01717 →
P47751 — 0.983 P47751 →
Q28596 — 0.981 Q28596 →
O93603 — 0.980 O93603 →
O46639 — 0.980 O46639 →
Q8BZ39 — 0.979 Q8BZ39 →
A1ZAX0 — 0.977 A1ZAX0 →
Q8ITC7 — 0.977 Q8ITC7 →
P21761 — 0.976 P21761 →
Q8ITC9 — 0.976 Q8ITC9 →
E7F7V7 — 0.976 E7F7V7 →
F1R332 — 0.976 F1R332 →
NMUR2 Neuromedin-U receptor 2 0.975 landscape →
Q58CW4 — 0.975 Q58CW4 →
Q924H0 — 0.974 Q924H0 →
O17239 — 0.973 O17239 →
O02300 — 0.972 O02300 →
NPY2R Neuropeptide Y receptor type 2 0.971 landscape →
Q7T3Q7 — 0.971 Q7T3Q7 →
Q75Z89 — 0.971 Q75Z89 →
Q8K458 — 0.971 Q8K458 →
O46635 — 0.971 O46635 →
PROKR2 Prokineticin receptor 2 0.971 landscape →
Q5U431 — 0.971 Q5U431 →